 |
|
A New Strategy in the War on Renal Cell Cancer
Hitting Multiple Targets With Limited Collateral Damage
Boris Pasche, MD, PhD
JAMA. 2006;295:2537-2538.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
An estimated 38 890 individuals will be diagnosed as having renal cell carcinoma (RCC) in the United States in 2006 and approximately 12 840 patients will die from the disease.1 RCC is the most common malignant lesion of the kidney and accounts for 85% of all renal neoplasms and 3% of all adult malignancies.2 The overall incidence of RCC has increased over the past 20 years from 2% to 4% per year.3 While smoking, hypertension, and obesity have all been associated with RCC risk, smoking has emerged as the most significant risk factor. Cigarette smokers have double the risk of RCC than nonsmokers and pipe and cigar smokers also have an increased risk of the disease.3 RCC occurs most often in individuals aged 50 to 70 years and affects men almost twice as often as women.4 Many patients with this cancer are being diagnosed at an earlier stage . . . [Full Text of this Article]
Author Affiliation: Contributing Editor, JAMA; and Division of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Ill.
RELATED ARTICLE
Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim A. Margolin, Jaime R. Merchan, George Wilding, Michelle S. Ginsberg, Jennifer Bacik, Sindy T. Kim, Charles M. Baum, and M. Dror Michaelson
JAMA. 2006;295(21):2516-2524.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Sunitinib (Sutent(R)): A novel agent for the treatment of metastatic renal cell carcinoma
Chouhan et al.
J Oncol Pharm Pract 2007;13:5-15.
ABSTRACT
|
